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Insomnia is a major public health problem considering its high prevalence, impact on daily life, co-
morbidity with other disorders and societal costs. Cognitive behavioral treatment for insomnia (CBTI)
is currently considered to be the preferred treatment. However, no meta-analysis exists of all studies
using at least one component of CBTI for insomnia, which also uses modern techniques to pool data and
to analyze subgroups of patients. We included 87 randomized controlled trials, comparing 118 treat-
ments (3724 patients) to non-treated controls (2579 patients). Overall, the interventions had significant
effects on: insomnia severity index (g ¼ 0.98), sleep efficiency (g ¼ 0.71), Pittsburgh sleep quality index
(g ¼ 0.65), wake after sleep onset (g ¼ 0.63) and sleep onset latency (SOL; g ¼ 0.57), number of awak-
enings (g ¼ 0.29) and sleep quality (g ¼ 0.40). The smallest effect was on total sleep time (g ¼ 0.16). Face-
to-face treatments of at least four sessions seem to be more effective than self-help interventions or face-
to-face interventions with fewer sessions. Otherwise the results seem to be quite robust (similar for
patients with or without comorbid disease, younger or older patients, using or not using sleep medi-
cation). We conclude that CBTI, either its components or the full package, is effective in the treatment of
insomnia.
© 2017 Elsevier Ltd. All rights reserved.Introduction
Insomnia is a major public health problem. The prevalence of
insomnia, which may be characterized by difficulty initiating or
maintaining sleep, with significant distress and impairments of
daytime functioning, is high: about a third of the population suffers
from insomnia symptoms, and about 10% fulfills the criteria for a
sleep disorder [1,2]. Insomnia has a high burden of disease, which
impacts daily life in different domains [3,4] and often persists for
many years [5]. The societal costs are substantial: poor sleepers cost
society about ten times as much as good sleepers [6]. These societal
costs are due to increased health care consumption but especially
caused by reduced work productivity and increased work absen-
teeism [6,7].hology, Faculty of Psychology
t 1, 1081 BT Amsterdam, The
).In addition, insomnia is strongly associated with other somatic
and mental health problems as well as with an increased mortality
rate [8e10]. Most notable is the association with cardiovascular
diseases [11e13] and with depression [14e16]. The nature of these
associations is still not clear but it has been suggested that hyper-
arousal and the chronic activation of stress responses is a possible
pathway between insomnia, depression and cardiac disease [13].
There are also indications that insomnia is a mediator in the
increased mortality rates after depression [17].
Treatment of insomnia is highly desirable, mostly to decrease
the burden of insomnia itself. But it might also contribute to a
decrease of the associated somatic and mental health problems
such as depression and cardiovascular risk.
Several meta-analyses have shown that benzodiazepine-
receptor agonists are effective in enhancing sleep in the short
run, but with risks of negative side effects and limited evidence
for their long-term efficacy [18e20]. Various non-pharmacological
treatments have been developed as alternatives. These non-
pharmacological treatments can be classified as educational
(psycho-education, sleep hygiene), behavioral (relaxation, sleep
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(identifying and challenging dysfunctional thoughts and excessive
worries about sleep; [21e26]). Since the 1990s it has become
popular to offer these non-pharmacological treatments in (various)
combinations. These combinations are usually referred to as
cognitive behavioral therapy for insomnia (CBTI).
Several excellent (systematic) reviews and meta-analyses have
been written on CBTI; they conclude that CBTI is effective [27e33]
in primary [34] and comorbid [35,36] insomnia and CBTI is at least
as effective as pharmacotherapy [37,38]. As a result, the American
College of Physicians recently recommended CBTI as the initial
treatment for all adults with insomnia [39]. Even though some of
these reviews pooled the data of individual studies [e.g.,
[28,29,35]], to our knowledge, no recent meta-analysis exists that
includes all CBTI studies and that uses modern techniques to pool
data and to analyze the subgroups of patients which might benefit
most from CBTI.
The aim of this meta-analysis is to quantify the effects of
educational, behavioral and cognitive therapies for insomnia, based
on all available randomized controlled trials, and to perform sub-
group analysis as a function of several potential moderators (e.g.,




We carried out a comprehensive literature search in PubMed,
PsycINFO, EMBASE and the Cochrane central register of controlled
trials. We combined terms indicative of insomnia (e.g., insomnia,
sleep disorders, sleep initiation and maintenance disorders) with
those of psychological treatment (e.g., psychotherapy, cognitive
therapy, behavior therapy). For example for PsycINFO we used
(DE¼(“sleep disorders” or “insomnia”)) and (DE¼(“psychotherapy”
or “behavior therapy” or “cognitive behavior therapy” or “cognitive
therapy”)). We searched all literature up to December 2015. Titles
and abstracts were screened by one person (AvS, TvdZ, AK or JL).
Only those records that were definitely not suitable (e.g., not a
randomized trial, a biological or medical treatment) were excluded
in this phase. We retrieved the full papers of the remaining 196
references. Those papers were examined independently by two of
the four researchers (AvS, TvdZ, AK or JL). In case of disagreement
the paper was discussed with the third and fourth reviewer until
consensus was achieved.Inclusion criteria
We used the following inclusion criteria: 1) the study had to be a
randomized controlled trial (RCT), 2) investigating CBTI or at least
one component of it, 3) for adults of 18 y or older, 4) with insomnia,
5) in comparison with a non-active control group (e.g., waitlist
control, care-as-usual, or a minimal intervention such as psycho-
education about sleep or sleep hygiene information), 6) reporting
on sleep diary outcomes. We identified the following treatments as
being part of CBTI: relaxation, sleep restriction, stimulus control,
paradoxical intention, and identifying and challenging dysfunc-
tional thoughts (about sleep). We excluded all other therapies such
as interpersonal therapy, bright light therapy, exercise and
biofeedback. Cognitive distraction was also excluded because it
only encompassed advice on topics to think about (e.g., a recipe or a
plot of a television show) or things to do (e.g., to read a book or
watch television). We also excluded studies: aimed at children or
adolescents, at tapering of medication, which used outcomes such
as fatigue instead of sleep, or which were aimed at treating another
mental health disorder and reported insomnia as a secondary
outcome. We also excluded studies with insufficient information to
calculate the effect size (e.g., those presenting scores in a plot
without providing means, standard deviations or other relevant
statistics).Data extraction
We coded the following characteristics of the studies: 1) year of
publication, 2) setting where patients were recruited (community,
primary care, other care facilities, university), 3) the definition of
insomnia that was used, 4) co-morbidity (e.g., insomnia in chronic
pain patients), 5) age group (young adults, older adults or all
adults), 6) the treatment format (individual, group or self-help), 7)
the number of treatment sessions, 8) the use of sleep medication
(allowed, not allowed or not reported), 9) the type of control group
(e.g., waitlist, no treatment), 10) the number of patients included in
the treatment and control group, and 11) type of intervention. We
distinguished four categories of interventions: a) full CBTI which
had to include an educational component as well as a behavioral
and cognitive one, b) behavioral therapy which had to include
both stimulus control and sleep restriction (with or without an
educational component), c) relaxation, and d) “other” which
included e.g., stimulus control only or paradoxical intention only.
Two independent assessors coded each study and differences were
A. van Straten et al. / Sleep Medicine Reviews 38 (2018) 3e16 5discussed by the review team until consensus was reached (AvS,
TvdZ, AK, or JL).
Quality assessment
We assessed the validity of the studies using the criteria sug-
gested by the Cochrane handbook [40]: 1) adequate sequence
generation, 2) concealment of allocation, 3) adequate handling of
incomplete outcome data, and 4) selective reporting of data.We did
not assess the blinding of patients or therapists since this is
impossible in psychotherapy research nor did we assess blinding of
outcome assessors since all reported outcomes are based on self-
report. Two reviewers conducted the quality assessment indepen-
dently of each other (AvS, TvdZ, AK, or JL).
Meta-analyses
We examined the effects as observed immediately after treat-
ment (post-test). We calculated between group effect sizes for all
individual studies using Hedges' g. This is the standardized mean
differences (or Cohen's d) after adjusting for small sample sizes
[41,42]. The effect size represents the difference between two
groups in number of standard deviations. Effect sizes of 0.56e1.2
can be assumed to be large, while effect sizes of 0.33e0.55 are
moderate, and effect sizes of 0e0.32 are small [43]. To calculate
those effect sizes, we used the available statistics as published in
the papers (e.g., means and standard deviations, mean difference
score and 95% confidence interval).
To calculate the individual effect sizes as well as the pooled
mean effect size we used the computer program Comprehensive
meta-analysis (CMA) version 3.3.070 for Windows, developed for
support in meta-analysis (www.metaanalysis.com). We first per-
formed the analyses on all studies and then checked for outliers. An
outlier was defined as a study in which the 95% confidence interval
around the effect size did not overlap with the 95% confidence in-
terval around the pooled effect size. We then repeated the analysis
without the identified outliers.
As we expected considerable heterogeneity, we calculated
pooled effect sizes with the random effects model. We tested het-
erogeneity under the fixed effects model using I2 which describes
the variance between studies as a proportion of the total variance. A
value of 0% indicates no observed heterogeneity and larger values
show increasing heterogeneity. We calculated 95% confidence in-
tervals (CI) around I2, using the non-central Chi squared-based
approach within the heterogi module for Stata.
We tested for publication bias by visually inspecting the funnel
plot and by conducting the Egger's test of the intercept. We used
the Duval and Tweedie [44] trim and fill procedure to estimate the
effect size after the publication bias had been taken into account. It
also provides an estimate of the number of missing studies.
In addition, we performed univariate subgroup analyses on
three different outcome variables: sleep onset latency (SOL), sleep
efficiency (SE) and insomnia severity index (ISI). We chose SOL
because this was the most frequently used outcome variable, SE
because this is often described as the preferred primary outcome in
insomnia research and ISI because this questionnaire is gaining
popularity rapidly as an outcome and is much easier to collect than
a sleep diary. For these three variables we tested whether the effect
size was significantly related to treatment, patient or study vari-
ables. We used themixed effects model, which pools studies within
subgroups with the random effects model, but tests for significant
differences between subgroups with the fixed effects model. Lastly,
we conducted multivariate meta regression analysis. We only
included variables that were univariate associated with the
outcome with a p-value of 0.25 or less. Two variables wereexcluded because of collinearity: type of treatment (which was
collinear with yes/no full CBTI treatment) and number of sessions
(which was collinear with treatment format since self-help in-
terventions cannot be divided into discrete sessions). We entered
all the variables in the model simultaneously and calculated stan-
dard regression coefficients. Finally, we reported the overall pro-
portion of the total between-study variance which is explained by
the model (R square).
Results
Selection of studies
The titles and abstracts of 1727 references were screened (after
removal of 290 duplicates). We excluded 1503 references and
retrieved full-text papers of the remaining 224 references. A total of
137 papers did not fulfill our inclusion criteria (Fig. 1). We included
87 papers on RCTs inwhich (a component of) CBTI was examined in
comparison to a non-treatment control group [45e131]. Some
studies had more than two arms and examined different active
interventions in comparison to a control. Of the 87 studies, 63
examined one intervention, 18 examined two interventions, five
studied three interventions and one studied four interventions. The
total number of comparisons was therefore 118. There were 6.303
patients included in the studies, 3.724 in the intervention groups
and 2.579 in the control groups.
Characteristics of included studies
The first studies were published in 1974 but the majority of
studies (n ¼ 62; 71%) were published in or after the year 2000
(Table 1). Most studies recruited people from the general popula-
tion (n ¼ 59; 68%). A minority of the studies recruited people
through care facilities (primary care or specific care settings,
n ¼ 20; 23%) and many of those studies additionally recruited via
general media. The remaining eight studies (9%) recruited partici-
pants through universities. Some studies excluded older patients
(n ¼ 18; 21%), while others specifically focused on the elderly
(n ¼ 20; 23%). The remaining studies either included both younger
and older adults (n ¼ 30; 34%) or did not specify which age cate-
gories were eligible for the study (n ¼ 19; 22%). Some studies
specifically examined insomnia in the context of another somatic
disorder (n ¼ 15; 17%) or a mental disorder (n ¼ 5; 6%) but most
studies aimed to examine primary insomnia and therefore
excluded patients with mental or somatic illnesses (n ¼ 45; 52%).
For the remaining studies comorbidities were allowed but it was
not always clear whether or not they excluded patients with severe
illnesses (n ¼ 22; 25%). About half of the studies allowed the use of
sleep medication during the study (n ¼ 40; 46%), while in the other
half of the studies sleep medicationwas either not allowed (n¼ 37;
43%) or it was not reported how the use of sleep medication was
handled (n ¼ 10; 11%).
Out of the 118 interventions included in this meta-analysis 51
(43%) consisted of full CBTI (educational component as well as a
behavioral and cognitive one), 13 (11%) of behavioral therapy
(stimulus control and sleep restriction but no cognitive element),
23 (19%) of relaxation (without any other treatment element) while
the remaining 31 interventions (26%) consisted of “other” treat-
ments such as paradoxical intention only, or stimulus control only.
About a third of the treatments (n ¼ 35; 30%) was offered in group
format, about half (n ¼ 57; 48%) was offered as individual face-to-
face therapy while the remaining studies examined self-help
treatments (either through books, audio or the internet, n ¼ 26;
22%). The individual or group treatments typically took up to six
sessions (n ¼ 71; 60%). Of the 87 studies, 41 used a waitlist control
Fig. 1. Flow-chart of studies included in the meta-analysis on psychological treatment for insomnia (inception to 10 january 2016).
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desensitization; 23%) and 12 offered psycho-education (14%).
Quality assessments
Out of all 87 studies 38 (44%) reported an adequate sequence
generation for their randomization while the remaining 49 studies
did not report how they handled this. Only 23 studies (26%) re-
ported that their random allocation had been concealed. For the
other 64 studies (74%) this remained unclear. About half of the
studies (n ¼ 45; 52%) handled their missing data well by per-
forming intention-to-treat analyses. For another 24 studies (27%) it
was clear that missing cases had been dropped from their analysis.
For the other 18 studies (21%) it remained unclear how many pa-
tients were randomized, how many patients had dropped out and
how missing data were handled.
We used self-report sleep diary data to extract our outcome
data. Many different variablesmight be extracted from a sleep diary
and this was reflected in the included studies. Of all the 118 com-
parisons 108 calculated SOL. This is the time it takes to fall asleep
after going to bed and turning the lights out/attempting to sleep.
The SE, the percentage of time having slept while being in bed, was
calculated for 79 comparisons, total sleep time (TST) for 91, the time
being awake after sleep onset (WASO) for 71, sleep quality (SQ) for
40 and the number of awakenings during the night (NWAK) for 36
comparisons. Out of all 87 studies 38 also included the insomnia
severity index (ISI [132]) as an outcome measure and 19 included
the Pittsburg sleep quality index (PSQI [133]).
Overall effects
The CBTI interventions had positive statistically significant ef-
fects on all reported sleep outcomes (Table 2). The ISI showed the
largest effect (g ¼ 0.98) but large effects were also obtained for SE
(g ¼ 0.71), PSQI (g ¼ 0.65), WASO (g ¼ 0.63) and SOL (g ¼ 0.57).
Small to moderate effect sizes were observed for NWAK (g ¼ 0.29)and SQ (g ¼ 0.40). The smallest effect was on TST (g ¼ 0.16). Since
there were studies with extremely high effect sizes as well as
studies with extremely low effect sizes, deleting the outliers did not
influence the effect sizes substantially. It did reduce the percentage
of heterogeneity (I2). Heterogeneity remained quite high for the ISI
and the SQ but was small to moderate for all outcomes based on
sleep diaries. Of the 87 studies, 24 (28%) examined more than one
treatment while using only one control group for each study. This
means that the comparisons from these studies were not inde-
pendent of each other which may have resulted in an artificial
reduction of heterogeneity. We examined the possible effects by
conducting sensitivity analyses in which we included only one
comparison per study. First, we included only the comparison with
the largest effect size from that study and then we conducted
another analysis in which we included only the smallest effect size.
The resulting effect sizes and heterogeneity statistics were highly
comparable with the ones found in the overall analyses (Table 2)
and therefore not shown.
Association between effect and treatment, patient and study
variables
We studied the association between the effect size on SOL, SE
and ISI on the one hand and different treatment, patient and study
variables on the other (Table 3). Overall the results were mixed and
depended on the outcome variable.
First, we describe the results for SOL. SOL was significant
(p < 0.05) related to type of treatment, age, and year of publication:
effect sizes were higher for relaxation and “other” treatments than
for CBTI or behavioral treatments and higher for young adults than
for older adults. There seems to be a U-shape association between
SOL and the year of publication: the oldest studies have the highest
effect sizes, but after the 90s the effect sizes start to increase again.
There were also significant associations for the use of sleep medi-
cation and concealment of allocation. In these cases effect sizes
were higher for studies that did not report the use of sleep
Table 1
Characteristics of the included studies on (elements of) CBT for insomnia.
Study Recruitment Definition insomnia Co-morbidity Age Interv Format F2F sessions N EXP Control
group
Nctrl
Alperson, 1979 [45] Comm SOL  30 min Allowed 17e54 Relax þ SC Group 2 7 WL 7
Arnedt, 2011 [46] Care SOL  30 min,  3 n/wk, 
1 mo þ ISI  8
Alcohol 18e65 CBTI Indiv 4 9 Plac 8
Arnedt, 2013 [47] Care Wake time > 60 min þ SE < 85% Excluded 18e65 CBTI Phone 4e8 18 PE 15
Ascher, 1979 [48] Comm SOL  60 min,  3 n/wk Excluded 18þ Pdox Indiv 4 8 - 9









Borkovec, 1976 [50] Univ Average SOL  30 min Allowed e Relax Group 4 12 - 12
Bothelius, 2013 [51] Care Poor sleep > 1 m mo þ daytime imp Excluded 18þ CBTI Group 5 32 WL 34
Broomfield, 2003 [52] Univ SOL  30 min, > 3 n/wk þ PSQI > 5 Excluded 16e65 Pdox SHp n/a 17 - 17
Buysse, 2011 [53] Care DSM-IV and ICSD-2 insomnia diagnosis Allowed elderly Behavioral Indiv 2 42 PE 40
Carr-Kaffashan, 1979 [54] Comm Average SOL  30 min,  6 mo Allowed 18þ Relax Indiv 4 16 Plac 14
Creti, 2005 [55] Comm No criteria Excluded 55þ Relax SHp n/a 14 - 13
Currie, 2000 [56] Care DSM-III insomnia diagnosis with SIS-D
and ICSD diagnosis
Pain <60 CBTI Group 7 32 WL 28


















Edinger 2005 [59] Comm Mean WASO  60 min Fibromyalgia 21e65 Behavioral Indiv 6 18 - 11
Edinger, 2003 [60] Primary care Difficulty initiating or maintaining
sleep  1 mo þ daytime imp
Excluded e BT Indiv 2 10 plac 10




























Ellis, 2015 [63] Comm Difficulty initiating or maintaining
sleep or early morning awakening,
 3 n/wk, < 3 mo
excluded e CBTI Indiv 1 20 WL 20
Epstein, 2007 [64] Comm SOL or WASO  30 min,  3 n/wk,
 2 wk þ daytime imp
Cancer 18þ Behavioral Group 4 40 PE 41
Epstein, 2012 [65] Comm SOL or WASO  45 min,  3 n/wk,
 6 mo þ day-time imp
Excluded 55þ PE þ SR
PE þ SC
























Espie, 2001 [67] Care ICSD difficulty falling/maintaining
sleep,  4 n/wk,  3 mo þ PSQI  5
Excluded e CBTI Group 6 74 WL 65
Espie, 2007 [68] Care ICSD/DSM-IV criteria of insomnia Allowed e CBTI Group 5 107 - 94
Espie, 2008 [69] Care SOL or WASO  30 min,  3 n/wk,
 3 mo þ PSQI  5
Cancer 18þ CBTI Group 5 100 - 50
Espie, 2012 [70] Comm poor sleep  3 n/wk,  3 mo þ daytime
imp þ SE < 80%
Excluded 18þ CBTI SHp n/a 55 WL 54
Freedman, 1976 [71] Univ SOL  60 m,  4 n/wk,  6 mo Excluded e Relax Indiv 6 6 PE 6
Friedman, 2000 [72] Comm SE < 80%, SOL >30 min, TST < 6h,
WASO > 30 min,  5 n/2wk
Excluded 55þ SC þ SR Indiv 5 16 PE 11
Harris, 2012 [73] Comm SOL > 30 min,  3 n/wk,  6 mo þ
daytime imp
Excluded 18e65 SC Indiv 5 20 PE 20
Haynes, 1974 [74] Univ NR e 18e21 Relax Group 6 7 plac 7
Ho, 2014 [75] Comm SOL or WASO  3 n/wk,  3










Irwin, 2014 [76] Comm SOL or WASO  3 n/wk,  3
mo þ daytime imp
Excluded 55þ PE þ SC þ
CT þ relax
group 16 50 PE 25
Jacobs, 2004 [77] Comm SOL > 60 min,  3 n/wk,  6 mo þ
daytime imp
Excluded 25e64 CBTI Indiv 4 15 Plac 15
Jansson, 2012 [78] Care SOL or WASO > 30 m,  3 n/wk,
 6 mo þ daytime imp
Hearing
problems
18e65 CBTI Indiv 7 17 WL 15









Jungquist, 2010 [80] Care SOL or WASO > 30 min, > 3 n/wk,
> 6 mo
Pain 25þ CBTI Indiv 8 19 Plac 9
Kaldo, 2015 [81] Comm Difficulty initiating or maintaining
sleep þ daytime imp þ ISI > 10
Excluded 18þ CBTI SHp n/a 73 Plac 75
Kapella, 2011 [82] Comm Difficulty initiating or maintaining
sleep, waking up too early or poor
quality sleep
COPD 45þ CBTI Indiv 6 9 plac 9













Lacks, 1983b [84] Comm WASO  30 min,  1 n/wk,  6 mo Excluded 17e59 SC Group 4 7 Plac 8
(continued on next page)
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Table 1 (continued )
Study Recruitment Definition insomnia Co-morbidity Age Interv Format F2F sessions N EXP Control
group
Nctrl









Lancee, 2015 [86] Comm SOL or WASO > 30 min,  3 n/wk,
 3 mo þ daytime imp þ ISI > 10
Excluded 18þ CBTI SHp n/a 36 WL 27
Lancee, 2016 [87] Comm SOL or WASO  30 min,  3 n/wk,
 3 mo þ ISI  10







Lichtstein, 1999 [88] Comm SOL or WASO  30 min,  3 n/wk,
 6 mo
Excluded e Relax Indiv 3 10 WL 10
Lichtstein, 2000 [89] Comm SOL or WASO  30 min,  3 n/wk,
 6 mo þ daytime imp
Illness 58þ Relax þ SC Indiv 4 23 WL 21
Lichtstein, 2001 [90] Comm SOL or WASO  30 min,  3 n/wk,



















Lovato, 2014 [92] Comm WASO > 30 min,  3 n/wk,
> 6 mo þ daytime imp
Exluded Older CBTI Group 4 86 WL 32
Manber, 2008 [93] Comm SOL or WASO  30 min, TST  6.5 h,
 3 n/wk
Depression 18e75 CBTI Indiv 7 15 Plac 15
McCrae, 2007 [94] Comm SOL > 31 min,  3 n/wk,  6 mo þ
daytime imp
Excluded 65þ SC þ SR Indiv 2 11 PE 11
Means, 2000 [95] Univ SOL or WASO  30 min þ poor
sleep  2 mo þ daytime imp
Excluded e Relax Indiv 3 28 - 29
Mimeault, 1999 [96] Comm SOL or WASO  30 min,  3 n/wk,










Morawetz, 1989 [97] Comm SOL or WASO > 30 min,  3 n/wk,
 6 mo þ daytime imp









Morin, 1988 [98] Comm WASO > 30 min,  3 n/wk,
 6 mo þ daytime imp
Excluded 55þ SC Group 6 9 WL 10
Morin, 1993 [99] Comm WASO > 30 min,  3 n/wk,
 6 mo þ daytime imp
Excluded 60þ CBTI Group 8 12 WL 12
Morin, 1999 [100] Comm SOL or WASO  30 min,  3 n/wk,
 6 mo þ daytime imp
Excluded 55þ CBTI Group 8 18 Plac 20
Morin, 2005 [101] Comm Poor sleep  3 n/wk Allowed 18þ CBTI SHp n/a 96 - 96









Norell-Clarke, 2015 [103] Comm Insomnia symptoms> 3 n/wkþ ISI> 10 Depression e CBTI Group 4 32 Plac 32
Pigeon, 2012 [104] Care SOL or WASO > 30 min,  3 n/wk,
 6 mo
Pain 35e75 CBTI Indiv 10 6 WL 4
Riedel, 1995 [105] Comm SOL > 30 min,  3 n/wk,  12 mo Excluded 60þ PE þ SR Group 4 25 WL 25
Riedel, 1998 [106] Comm SOL or WASO or early
awakening > 30 min,  3 n/wk,  6 mo
Excluded 19e80 SC Indiv 2 11 WL 10
Riley, 2010 [107] Comm SOL or WASO or early
awakening > 30 min,  3 n/wk,  6 mo
Excluded 18e65 SC þ SR SHp n/a 57 PE 33
Ritterband, 2009 [108] Comm Poor sleep  3 n/wk,  6 mo þ
daytime imp
Allowed 18e65 CBTI SHp n/a 22 WL 23
Ritterband, 2012 [109] Comm Poor sleep  3 n/wk,  6 mo þ daytime
imp þ average TST  6.5 h
Cancer 21þ CBTI SHp n/a 14 WL 14
Rybarczyk, 2002 [110] Care SOL  45 min or WASO  60 min or










Rybarczyk, 2005 [111] Care SOL  30 min/WASO  60 min/
TST  6.5 h,  3 n/wk,
 6 mo þ daytime imp
Illness 55þ CBTI Group 8 46 Plac 46
Savard, 2005 [112] Comm SOL or WASO > 30 min, SE < 85%, 3 n/
wk,  6 mo þ daytime imp
Cancer 18þ CBTI Group 8 27 WL 30
Savard, 2014 [113] Care ISI  8 or  2 nights of sleepmedication










Sivertsen, 2006 [114] Comm Poor sleep  3 mo þ daytime imp Allowed 55þ CBTI Indiv 6 18 Plac 12




e CBTI Indiv 8 50 Plac 50
Soeffing, 2008 [116] Comm SOL or WASO > 30 min,  3 n/wk,
 6 mo þ daytime imp
Excluded 50þ CBTI Indiv 8 20 Plac 27


















Strom, 2004 [119] Comm SOL/WASO/early awakening > 30 min,
 3 n/wk,  3 mo þ daytime imp
Excluded 18þ CBTI SHp n/a 54 WL 55
Swift, 2012 [120] Comm No in- or exclusion criteria Allowed 18þ CBTI Group 1day 75 WL 76
Talbot, 2014 [121] Comm ISI > 14 þ difficulty initiating or
maintaining sleep þ daytime imp
PTSD treatment 18e65 CBTI Indiv 8 29 WL 16
Taylor, 2010 [122] Care Average SE < 85%, 6 mo þ regular use
of sleep medication
Excluded 18þ SR Indiv 8 24 WL 22
Taylor, 2014 [123] Univ SOL or WASO > 30 min,  3 n/wk,
 3 mo þ daytime imp
Allowed 18e27 CBTI Indiv 6 17 WL 17
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Table 1 (continued )
Study Recruitment Definition insomnia Co-morbidity Age Interv Format F2F sessions N EXP Control
group
Nctrl













Van Straten, 2009 [125] Comm SOL/WASO/early awakening > 30 min,
 3 n/wk,  1 mo
Allowed 18þ CBTI SHp n/a 126 WL 121
Van Straten, 2013 [126] Comm SOL > 30 min,  3 n/wk,  3 mo Allowed 18þ CBTI SHp n/a 59 WL 59
Vincent, 2009 [127] Comm SOL or WASO > 30 min,  4 n/wk,
 6 mo þ daytime imp
Allowed 18þ CBTI SHp n/a 59 WL 59
Waters, 2003 [128] Comm SOL and (WASO > 30min or NWAK > 3)























Wu, 2006 [130] Comm SOL or WASO  30 min,  6 mo þ
daytime imp
Excluded e CBTI Group 16 19 Plac 19
Zwart, 1979 [131] Univ Average SOL  30 min Allowed e SC Group 4 9 WL 8
Abbreviations: AASM ¼ American Academy of Sleep Medicine; AT ¼ autogenic training; CD ¼ cognitive distraction; CMI ¼ comorbid insomnia; Comm ¼ community;
CT ¼ cognitive therapy; DSISD ¼ Duke structured interview for sleep disorders; F2F ¼ face-to-face; ICSD ¼ International classification of sleep disorders; imp ¼ impairment;
indiv ¼ individual; ISI ¼ insomnia severity index; NEXP ¼ number of patients in experimental condition; Nctrl ¼ number of patient in control condition; NWAK ¼ number of
awakenings; NR ¼ not reported; PE ¼ psycho-education; PI ¼ primary insomnia; plac ¼ placebo; PR ¼ progressive relaxation; PSQI ¼ Pittsburgh sleep quality index;
RDC¼ research diagnostic criteria; relax ¼ relaxation; SC¼ stimulus control; SE ¼ sleep efficiency; SHp ¼ self-help; SIS-D¼ structured interview for sleep disorders for DSM-
III-R; SOL ¼ sleep onset latency; SR ¼ sleep restriction; TST ¼ total sleep time; univ ¼ university; WASO ¼ wake after sleep onset; WL ¼ waitlist.
A. van Straten et al. / Sleep Medicine Reviews 38 (2018) 3e16 9medication and for studies that did not report allocation conceal-
ment. There were borderline significant (p < 0.10) associations for
SOL with treatment format (individual and group treatments yiel-
ded higher effect sizes than self-help), number of sessions (longer
treatments yielded better effect sizes than shorter treatments),
recruitment population (non-community samples yielded higher
effect sizes), and type of control (no treatment had highest effect
size). Overall, heterogeneity seemed to be moderate.
Second, we describe the results for SE. Some of the results for SE
were comparable to those of SOL. This means that there was a
(borderline) significant association with: type of treatment (higher
effect sizes for “other” treatment than for CBTI or behavioral
treatments), treatment format (higher effect sizes for individual
and group therapy than for self-help), number of sessions (higher
effect sizes for five or more sessions than for one to four), ageTable 2
Main post-test effects of insomnia treatments.























19 0.65 (0.51e0.79) 39 (0e64) 2.82
Wake after sleep onset
(WASO)
71 0.63 (0.53e0.73) 60 (46e68) 2.91
Without nine outliersd 62 0.66 (0.57e0.74) 40 (14e55) 2.78






















36 0.28 (0.16e0.40) 29 (0e52) 6.41
Without nine outliersg 34 0.28 (0.17e0.38) 11 (0e42) 6.41










95% CI ¼ 95% confidence interval; Nc ¼ number of comparisons; NNT ¼ number
needed to treat.
a Three lower and four higher; b Seven lower and seven higher; c No outliers present;
d Six lower and three higher; e Three lower and six higher; f Four lower and two
higher; g One lower and one higher; h Six lower and three higher.(higher effects for younger people than for older people), recruit-
ment population (higher effect sizes for patients recruited in other
ways than general media/community) and year of publication (the
most recent publications yielded the highest effect sizes). There
were also some differences between the results for SOL and SE
because SE was also (borderline) significantly associated with co-
morbidity (people with comorbid disorders obtained higher ef-
fects) and ITT (intention to treat) analysis (studies using ITT analysis
showed higher effects than studies which did not report this).
Third, we describe the results for ISI. ISI was significantly related
only to the type of control: studies with waitlist controls showed
higher effects than studies with other type of control groups. There
was furthermore a borderline significant association with alloca-
tion concealment: studies not reporting this yielded higher effect
sizes (Table 3).
We examined a number of variables which might be related to
each other (e.g., studies examining self-help might have included
younger people than studies examining individual therapy).
Therefore, we also performed a multivariate analysis (Table 4). The
multivariate model showed significant relations with SE and ISI for
treatment format. Self-help interventions performed worse than
individual face-to-face interventions. Two other significant asso-
ciations were related to study quality: studies that did not report
allocation concealment had higher effects on SOL and ISI, and
studies that did not report age had higher effects on SE and ISI.
Finally, two significant associations were related to study design:
studies with awaitlist control showed higher effect sizes on ISI than
studies with an information control (or other minimal in-
terventions) and more recent studies showed higher effect sizes on
SE than older studies.Publication bias
Visual inspection of the funnel plot seemed to indicate that
there was publication bias and this was confirmed by Egger's test
(p < 0.01 for SOL, SE and ISI). This means that there are studies
which are not published because of their small effects. Duval and
Tweedie have developed a method (implemented in CMA) which is
able to estimate how many studies are missing and what their ef-
fect sizewould have been [44]. It re-calculates the pooled effect size
Table 3
Post-test effects of insomnia treatment on SOL, SE and ISI: subgroup analyses.
Sleep onset latency (SOL) Sleep efficiency (SE) Insomnia severity index (ISI)
NC g (95% CI) I2 (95% CI p NC g (95% CI) I2 (95% CI p NC g (95% CI) I2 (95% CI p
Treatment variables
Full CBTI
Yes 44 0.47 (0.41e0.53) 51 (27e65) 0.25 47 0.63 (0.56e0.69) 70 (58e77) 0.41 34 0.82 (0.74e0.91) 75 (65e81) 0.98
No 64 0.61 (0.52e0.70) 44 (20e58) 32 0.69 (0.58e0.79) 70 (55e78) 4 1.03 (0.79e1.26) 48 (0e81)
Type of treatment
CBTI 44 0.47 (0.41e0.53) 51 (27e65) 0.03 47 0.63 (0.56e0.69) 70 (58e77) <0.01 34 0.82 (0.74e0.91) 75 (65e81) 0.67
Behavioral 12 0.38 (0.20e0.55) 45 (0e70) 13 0.68 (0.50e0.85) 67 (32e80) 2 0.90 (0.53e1.26) 80 n/ad
Relaxation 22 0.63 (0.46e0.80) 35 (0e60) 5 0.18 (0.09e0.45) 0.0 (0e64) e e e e
Other 30 0.72 (0.59e0.84) 42 (0e62) 14 0.87 (0.71e1.03) 72 (47e82) 2 1.12 (0.81e1.42) 0 n/ad
Treatment format
F2F individual 50 0.61 (0.51e0.71) 50 (27e63) 0.07 37 0.66 (0.56e0.77) 47 (17e64) 0.03 14 1.11 (0.94e1.28) 68 (37e80) 0.21
F2F group 33 0.59 (0.49e0.68) 42 (3e61) 17 0.90 (0.78e1.01) 79 (65e85) 9 0.98 (0.82e1.13) 48 (0e74)
Self help 25 0.42 (0.34e0.49) 42 (0e63) 25 0.52 (0.44e0.59) 71 (54e80) 15 0.68 (0.58e0.79) 78 (62e85)
Number of sessionsa
1e4 41 0.49 (0.38e0.60) 44 (13e61) 0.06 16 0.54 (0.39e0.69) 12 (0e52) 0.01 4 1.03 (0.79e1.27) 40 (0e79) 0.44
5e6 26 0.66 (0.56e0.76) 49 (11e67) 22 0.84 (0.73e0.95) 76 (63e83) 10 1.12 (0.96e1.29) 52 (0e75)
7 or more 16 0.68 (0.52e0.84) 43 (0e67) 16 0.88 (0.72e1.04) 57 (13e74) 9 0.89 (0.68e1.10) 74 (40e85)
n/a (self help) 25 0.42 (0.34e0.49) 42 (0e63) 25 0.52 (0.44e0.59) 71 (54e80) 15 0.68 (0.58e0.79) 78 (62e85)
Patient variables
Population
Community 79 0.47 (0.41e0.53) 51 (34e62) 0.10 59 0.60 (0.54e0.66) 70 (61e77) 0.10 26 0.82 (0.73e0.91) 78 (68e84) 0.59
Other 29 0.64 (0.54e0.74) 29 (0e54) 20 0.77 (0.66e0.88) 64 (37e77) 12 0.93 (0.78e1.08) 54 (0e74)
Comorbidity
Yes 20 0.63 (0.52e0.75) 36 (0e62) 0.38 20 0.87 (0.75e0.99) 55 (16e72) 0.03 14 0.90 (0.76e1.05) 68 (37e80) 0.65
No 88 0.49 (0.43e0.55) 49 (33e60) 59 0.58 (0.52e0.64) 70 (61e77) 24 0.82 (0.73e0.91) 77 (65e83)
Sleep medication
Allowed 51 0.46 (0.40e0.52) 49 (25e63) <0.01 41 0.58 (0.52e0.65) 70 (57e77) 0.22 25 0.77 (0.68e0.86) 76 (64e83) 0.13
Not allowed 4710 0.59 (0.49e0.68) 48 (22e62) 35 0.76 (0.66e0.87) 69 (55e77) 11 1.06 (0.89e1.22) 62 (10e79)
Not reported 0.93 (0.69e1.17) 0 (0e53) 3 0.99 (0.65e1.32) 0 (0e73) 2 1.58 (0.91e2.25) 0 n/ad
Ageb
Younger adults only 21 0.70 (0.57e0.84) 0 (0e41) 0.02 13 0.99 (0.84e1.15) 0 (0e49) <0.01 10 1.02 (0.84e1.19) 72 (38e84) 0.16
All adults 36 0.42 (0.35e0.49) 52 (24e66) 29 0.55 (0.49e0.63) 71 (56e79) 19 0.73 (0.63e0.84) 78 (65e85)
Older adults only 24 0.52 (0.40e0.64) 48 (7e67) 27 0.82 (0.71e0.94) 72 (58e80) 6 1.11 (0.92e1.31) 0 (0e61)
Not reported 27 0.63 (0.51e0.75) 52 (17e68) 10 0.34 (0.18e0.50) 0 (0e53) 3 0.68 (0.41e0.95) 35 (0e81)
Study variables
Year of publication
1970e1979 16 1.03 (0.80e1.27) 0 (0e45) <0.01 e e e e <0.01 e e e e 0.82
1980e1989 16 0.73 (0.53e0.92) 52 (0e72) e e e e e e e e
1990e1999 6 0.35 (0.07e0.64) 0 (0e61) 7 0.56 (0.30e0.83) 55 (0e79) 2 1.15 (0.66e1.64) 0 n/ad
2000e2009 37 0.41 (0.32e0.49) 9 (0e39) 38 0.46 (0.38e0.55) 58 (37e70) 8 0.71 (0.54e0.89) 82 (62e89)
2010þ 33 0.53 (0.46e0.60) 64 (46e75) 34 0.77 (0.70e0.85) 74 (62e80) 28 0.87 (0.78e0.96) 73 (58e80)
Type of control
No treatment 21 0.66 (0.54e0.77) 53 (13e70) 0.09 9 0.57 (0.44e0.70) 77 (50e86) 0.27 3 0.63 (0.45e0.81) 88 (50e94) 0.03
Waitlist 54 0.49 (0.43e0.56) 53 (33e65) 43 0.68 (0.61e0.75) 76 (68e82) 25 0.95 (0.85e1.04) 76 (64e83)
Placebo 20 0.47 (0.34e0.61) 50 (5e69) 15 0.60 (0.45e0.74) 51 (0e72) 8 0.79 (0.60e0.97) 32 (0e69)
PE/other 13 0.45 (0.28e0.62) 0 (0e49) 12 0.59 (0.42e0.77) 0.0 (0e50) 2 0.41 (0.07e0.90) 0 n/ad
Allocation sequence
Adequate 43 0.49 (0.43e0.55) 62 (44e72) 0.51 46 0.67 (0.60e0.73) 76 (67e81) 0.13 27 0.86 (0.77e0.94) 78 (68e84) 0.53
Not reported 65 0.57 (0.48e0.65) 33 (4e50) 33 0.56 (0.44e0.67) 53 (25e68) 11 0.79 (0.60e0.98) 56 (0e76)
Allocation concealed
Yes 26 0.39 (0.32e0.47) 53 (2e~69) <0.01 26 0.58 (0.50e0.65) 73 (58e81) 0.54 14 0.67 (0.56e0.78) 74 (52e84) 0.08
Not reported 82 0.63 (0.56e0.70) 38 (16e53) 53 0.71 (0.63e0.79) 67 (55e75) 24 1.03 (0.92e1.15) 67 (46e77)
Study drop-out
Unknown 11 0.71 (0.46e0.97) 61 (7e78) 0.62 2 0.13 (0.44e0.69) 0 n/ad 0.21 e e e e 0.25
0e9% 34 0.58 (0.47e0.70) 14 (0e44) 28 0.66 (0.54e0.78) 10 (0e44) 13 0.90 (0.73e1.08) 65 (26e79)
10e19% 47 0.50 (0.43e0.57) 57 (37e68) 32 0.68 (0.61e0.76) 80 (73e85) 17 0.95 (0.94e1.05) 77 (62e85)
20% or more 16 0.46 (0.34e0.57) 52 (0e71) 17 0.55 (0.44e0.66) 73 (54e82) 8 0.61 (0.46e0.75) 68 (13e83)
ITT analyses
Yes 51 0.51 (0.44e0.57) 62 (47e71) 0.67 50 0.66 (0.60e0.73) 75 (67e80) 0.09 33 0.83 (0.75e0.91) 74 (63e81) 0.67















intercept p < 0.01
CBTI ¼ cognitive behavioral treatment for insomnia; F2F ¼ face-to-face; ITT ¼ intention to treat; PE ¼ psycho-education; WASO ¼ wake after sleep onset.
a Self help treatments excluded.
b Studies not reporting inclusion range for age were excluded (WASO, n ¼ 6; SQ, n ¼ 3).
c Trim and fill procedure which estimates the number of missing studies (number that needs to be added) and produces the effect size after adding those studies.
d The 95% CI of I2 cannot be calculated when the number of groups is lower than three.
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Table 4
Association between post-test treatment effects and treatment-, patient- and study variables (standardized regression coefficients of multivariate meta regression analyses).
Sleep onset latency (SOL) Sleep efficiency (SE) Insomnia severity index (ISI)
g (95% CI) p g (95% CI) p g (95% CI) p
Treatment variables
Full CBTI
Yes Ref 0.56 n/a n/a
No 0.08 (0.18 to 0.33)
Treatment format
F2F individual Ref 0.62 Ref 0.03 Ref 0.05
F2F group 0.04 (0.23 to 0.16) 0.33 (0.04e0.62) 0.47 (1.01 to 0.08)
Self help 0.13 (0.38 to 0.13) 0.05 (0.36 to 0.26) 0.56 (1.01 to 0.11)
Patient variables
Population
Community Ref 0.55 Ref 0.28 n/a
Other 0.06 (0.14 to 0.26) 0.16 (0.13 to 0.45)
Comorbidity
Yes n/a Ref 0.78 n/a
No 0.05 (0.36 to 0.27)
Sleep medication
Allowed Ref 0.28 Ref 0.65 Ref 0.34
Not allowed 0.02 (0.18 to 0.23) 0.13 (0.15 to 0.41) 0.37 (0.87 to 0.14)
Not reported 0.28 (0.07 to 0.63) 0.06 (0.56 to 0.69) 0.01 (0.94 to 0.92)
Age
Younger adults only Ref 0.42 Ref 0.01 Ref 0.02
All adults 0.17 (0.41 to 0.08) 0.28 (0.62 to 0.06) 0.61 (1.07 to 0.14)
Older adults only 0.20 (0.46 to 0.06) 0.22 (0.58 to 0.14) 0.28 (1.00 to 0.43)
Not reported 0.14 (0.38 to 0.11) 0.70 (1.13 to 0.27) 0.81 (1.43 to 0.19)
Study variables
Year of publication 0.001 (0.012 to 0.009) 0.85 0.02 (0.001 to 0.05) 0.06 n/a
Type of control
No treatment Ref 0.16 n/a Ref <0.01
Wait list 0.10 (0.34 to 0.14) 0.60 (0.03 to 1.17)
Placebo 0.27 (0.55 to 0.01) 0.33 (0.33 to 0.99)
Info/other 0.29 (0.62 to 0.05) 0.99 (1.91 to 0.08)
Allocation sequence
Adequate n/a Ref 0.48 n/a
Not reported 0.11 (0.19 to 0.42)
Allocation concealed
Yes Ref <0.01 n/a Ref 0.02
Not reported 0.27 (0.08e0.46) 0.45 (0.09e0.81)
Study drop-out
0e9% n/a Ref 0.80 Ref 0.35
10e19% 0.09 (0.16 to 0.35) 0.22 (0.15 to 0.59)
20% or more 0.13 (0.17 to 0.42) 0.20 (0.23 to 0.63)
Unknown 0.11 (0.90 to 0.67) e
ITT analysis
Yes n/a Ref 0.61 n/a
No/not reported 0.07 (0.33 to 0.19)
R squared 0.30 0.32
95% CI ¼ 95% confidence interval; CBTI ¼ cognitive behavioral treatment; F2F ¼ face-to-face; g ¼ hedges g; ITT ¼ intention to treat; Ref ¼ reference group.
A. van Straten et al. / Sleep Medicine Reviews 38 (2018) 3e16 11while imputing the missing effect sizes. The results showed that 27
studies were missing for SOL, 21 for SE, and 13 for ISI. The effects
remained statistically significant after re-calculation but became
smaller (g ¼ 0.41 for SOL, g ¼ 0.49 for SE, and g ¼ 0.71 for ISI;
Table 3).Discussion
In this meta-analysis on 87 studies with 118 comparisons
we examined the effects of educational, behavioral and/or cogni-
tive treatments for insomnia. The overall effects were large on
insomnia severity (ISI; g ¼ 0.98), sleep efficiency (SE; g ¼ 0.71), the
Pittsburgh sleep quality Index (PSQI; g ¼ 0.65), wake after sleep
onset (WASO; g ¼ 0.63) and sleep onset latency (SOL; g ¼ 0.57).
Small to moderate effect sizes were observed for number of
awakenings (NWAK; g ¼ 0.28) and sleep quality (SQ; g ¼ 0.40). The
smallest effect was on total sleep time (TST; g ¼ 0.16). Heteroge-
neity was highest for self-reported outcomes (ISI and SQ) and more
moderate for sleep diary variables. Multivariate analysis showeddifferent associations for different sleep variables (SOL, SE and ISI).
We found that face-to-face interventions perform better than self-
help interventions (on SE and ISI but not on SOL), newer studies
and studies with a waitlist control yielded higher effect sizes (on SE
and ISI respectively), and studies that did not report age or allo-
cation concealment reported higher effect sizes (SOL and ISI, and
SE and ISI respectively).
The overall effects for insomnia treatments seem to be in line
with psychological treatments for other disorders such as depres-
sion (d ¼ 0.78 [134]), social phobia (d ¼ 0.70 [135]), panic disorder
with (d ¼ 0.78) or without agoraphobia (d ¼ 1.04 [136]). However,
the magnitude of the effects varied between the different outcome
parameters. Quite large effect sizes were obtained for scores on the
questionnaires of insomnia severity and sleep quality (PSQI) even
though there was considerable heterogeneity. The ISI and PSQI do
not rate the nocturnal symptoms of insomnia alone but also their
day-time consequences. However, it would be premature to
conclude from this that insomnia treatments are effective in
improving daytime functioning. We need studies examining
A. van Straten et al. / Sleep Medicine Reviews 38 (2018) 3e1612day-time functioning in more detail (e.g., examining fatigue,
work productivity, social activities) before we can make such a
statement.
Several indices derived from the daily sleep diary (SE,WASO and
SOL) also yielded high effect sizes, indicating that treatment was
very effective for improving sleep continuity. As previously re-
ported in other studies, the actual number of hours of sleep (TST)
improved only modestly. Post-hoc analysis did not seem to indicate
that TST was related to type of treatment indicating that TST was
not (artificially) reduced because of sleep restriction. Thus, the
findings indicate that treatment is mostly effective for improving
sleep continuity/efficiency and sleep quality, with some evidence of
improved daytime functioning as well. It must be noted, however,
that not all outcomes were reported in all studies. This hampers the
interpretation of the differences in effect sizes on the various
measures. Our knowledge about insomnia and its treatments
would be greatly enhanced if future randomized clinical trials used
the same outcome measures to estimate treatment effects [137].
Overall, CBTI treatments for insomnia are effective but the next
question is: can we explain the differences in effects between
studies (the heterogeneity)? First we examined this by comparing
the studies that used full CBTI to those who did not include all CBTI
components. There were no statistically significant differences
between the effects of those studies. Second we compared full CBTI
to different (combinations of) components. Univariate analyses
showed that relaxation works well for SOL and that “other” treat-
ments work the best on all sleep outcomes. The high effects for
“other” treatments compared with full CBTI are counterintuitive.
One explanation might be that these studies tend to be older and
these older studies tend to have poorer quality (no report on
randomization sequence or randomization concealment). The ef-
fect sizes for the full CBTI package seem to be similar to those for
behavioral techniques only. This brings into question the additional
effect of the cognitive modules. One recent study was aimed at this
question and compared behavioral treatment (BT) with cognitive
treatment (CT) and full CBTI [138]. Even though this study did not
demonstrate significant differences among the three treatments on
the post-test continuous ISI scores, there were some indications
that BTworked faster than CT but that the effects of CT lasted longer
than those of BT. Therefore, to make use of both effects, the authors
recommended full CBTI. Our current meta-analysis, which did not
include long-term follow-ups, can neither endorse nor reject this
recommendation.
Another reason for the failure to detect clear and consistent
differences in effects between the different treatments is that there
is considerable variety in the treatments within one category (e.g.,
full CBTI). This has been described previously with respect to sleep
restriction treatment [139]: there was a great variability in the way
the average number of hours asleep was calculated, the minimum
number of hours in bed, how bed and rise times were positioned,
what was the sleep efficiency criterion for extending the sleep
window, for howmany days this criterion should be reached before
actually extending etc. In all likelihood, these variations also exist
for the other CBTI elements. Our data support this idea since we
demonstrated quite large 95% confidence intervals for heteroge-
neity within the different treatment subgroups. Ultimately we need
to standardize our treatment components and examine differences
in effect by direct comparisons. We recommend that more
dismantling studies be performed.
The treatment format was significantly related to all studied
sleep outcomes. More specifically: self-help interventions seem to
performworse than face-to-face interventions, especially on SE and
ISI. This is in contrast to studies on other mental disorders which
often yield a similar or quite similar effect size for self-help in-
terventions compared with face-to-face interventions [140,141].Moreover, some of the recent studies on self-help interventions
demonstrated very high effect sizes, even thosewithout any human
support [64,98]. Since insomnia is so prevalent and self-help in-
terventions are much easier to offer than face-to-face treatments
against lower costs because of reduced therapeutic input, we
conclude that self-help interventions are worthwhile as a first step
of treatment. But sufficient face-to-face options need to be available
for those who do not recover. Furthermore, we urgently need
studies comparing the two treatment formats directly since two
recent studies showed mixed results with one not finding differ-
ences in effect [142] and the other finding face-to-face treatment
superior to online treatment [87].
It remains unclear to what extent the number of treatment
sessions is important to obtain optimal effects. There are some
indications from the univariate analysis that one to four session
treatments yield lower effect sizes than treatments which are
composed of more than four sessions. However, these results are
not very robust and do not apply to the ISI. It was not possible to
test the effect of the number of sessions in a multivariate analysis
since the self-help interventions all had zero sessions and this
caused collinearity. The only study that directly compared the
treatment duration (one, two, four and eight sessions; [61])
concluded that a duration of four sessions was optimal. Since
Edinger and colleagues [61] concluded that four sessions were
optimal, and we have indications that five or more sessions are
more effective, we conclude that one to three session treatments
seem to be less effective than longer treatments. However, more
studies directly comparing treatment length (and costs) are needed
to establish optimal treatment length.
Interestingly, there seems to be an association between publi-
cation year and treatment effect. For SE the newest studies (after
2010) showed significantly higher effect sizes than those published
between 1990 and 2010. There were no studies measuring SE
before 1990. For SOL, there seemed to be a U-shaped association:
the oldest studies showed the highest effects. Effect sizes then
decreased over time but the newest studies yielded higher effects
again. The association disappeared in the multivariate analysis but
this might be because in this analysis we used the actual publica-
tion year instead of categories. Furthermore, we tested for a linear
relationship and not for a U-curved relationship. A possible
explanation for the U-curve in SOL is the variation in study design
over time. The older studies (performed in the 1970s) more often
used homogeneous samples (young, without comorbidity, without
sleep medications). They were also smaller (fewer patients) and
less methodologically rigorous and therefore more susceptible to
different types of bias. These methodological shortcomings might
have led to higher effects. This is also in line with some of the other
results of the multivariate analysis: in studies of poorer methodo-
logical quality the interventions seemed to perform better. Studies
that did not report age or did not report the way they concealed
treatment allocation showed better results than those who did.
However, it might still be possible that the treatments offered in the
1970s were truly more effective than those offered later on. The
majority of these studies focused on either relaxation or paradox-
ical intention. Maybe these treatments are indeed effective but
have been pushed aside by the current fashion of CBTI? After all,
this also occurred in depression treatment where it has become
state-of-the-art to offer CBTI even though there is no conclusive
proof that CBTI actually works better than other treatments [134].
More research is needed in which older insomnia treatments are
directly compared with newer ones.
The treatment effects were not significantly related to the
presence of comorbidity, the allowance to use sleep medication, or
to age. This is in line with previous reviews of insomnia treatments
which argued that CBTI is effective for younger and older adults, for
A. van Straten et al. / Sleep Medicine Reviews 38 (2018) 3e16 13patients with and without comorbidities, for medication-free pa-
tients as well as for chronic hypnotic users [32].
An important limitation of this meta-analysis is that we only
could include studies of which the results were published. There
were indeed indications of publication bias. This suggests that the
actual effects of CBTI on insomnia might be smaller although still
significant. Another limitation is that not all of the studies used the
same outcome measure. Differences in effects between outcomes
might therefore reflect differences between studies rather than real
differences in effect. Finally, many quality criteria were not met by
the studies which might mean that we overestimate the true
effectiveness.
Despite the limitations we conclude that CBTI, either its com-
ponents or the full package, is effective in the treatment of
insomnia. Face-to-face treatments and treatments of at least four
sessions seem to be more effective than self-help interventions or
face-to-face interventions with fewer sessions. Otherwise the re-
sults seem to be quite robust (similar for patients with or without
comorbid disease, younger or older patients, using or not using
sleep medication). We need more high quality research, comparing
different treatment components directly with one another, to un-
derstand whether or not full CBTI is more effective than its separate
components and whether or not there are other (older) treatments
that are actually as effective as CBTI.Practice points
 Cognitive behavioral treatment for insomnia is effective
with large overall effects on insomnia severity, sleep ef-
ficiency, wake after sleep onset, and sleep onset latency.
The magnitude of these effects is in line with psycho-
logical treatments for other disorders.
 The smallest effects of cognitive behavioral treatment for
insomnia are found for total sleep time.
 Face-to-face treatments and treatments of at least four
sessions seem to be more effective than self-help in-
terventions or face-to-face interventions with fewer
sessions.
Research agenda
Future studies on cognitive behavioral treatment for
insomnia should focus on:
 Determining which treatment components are essential
for delivering cognitive behavioral treatment for
insomnia
 Comparing face-to-face treatments for insomnia with
their online counterpart
 Evaluating the optimal treatment length for cognitive
behavioral treatment for insomnia
 Directly comparing earlier insomnia interventions (e.g.,
relaxation) to newer ones (e.g., CBTI)
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